Related Experiment Video
Updated: Jun 25, 2026
16:24
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole
William R Miller1, Alexey Larionov, Lorna Renshaw
1Breast Research Group, University of Edinburgh, Edinburgh, United Kingdom. w.r.miller@ed.ac.uk
Summary
This study identifies genetic markers that predict response to letrozole in breast cancer patients. Understanding these molecular differences can improve treatment selection and guide the development of new therapies for resistant tumors.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Letrozole is an endocrine agent used for hormone-dependent breast cancer.
- Current treatment response rates for letrozole are suboptimal, necessitating new predictive markers and resistance mechanism insights.
Purpose of the Study:
- To identify novel molecular markers that predict clinical response to letrozole in breast cancer.
- To understand the molecular mechanisms underlying resistance to aromatase inhibitors.
Main Methods:
- Sequential tumor biopsies from patients receiving neoadjuvant letrozole were analyzed.
- High-density microarray expression profiling was correlated with clinical response assessed by tumor volume changes.
Main Results:
- 37 out of 52 patients (71%) responded to letrozole.
- Bioinformatic analysis revealed 205 genetic covariables distinguishing responders from non-responders.
- Ribosomal protein expression patterns at baseline and after treatment differentiated responsive and resistant tumors.
Conclusions:
- This study is the first to report genetic covariables and molecular processes differentiating tumors responsive and resistant to aromatase inhibitors.
- Identifying these molecular phenotypes is crucial for optimizing aromatase inhibitor use and developing novel therapeutic strategies for resistant breast cancer.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...